Curis Inc. (CRIS, Financial) experienced a notable stock price increase of 5.08%, reaching $4.55 per share with a trading volume of 39,110 shares and a turnover rate of 0.65%. The stock showed a volatility of 7.51% during the session.
Recent financial reports reveal that Curis Inc. generated revenue of $2.55 million but reported a net loss of $11.80 million, resulting in an earnings per share (EPS) of -$2.03. The company's gross profit stood at $2.47 million, and its price-to-earnings (P/E) ratio is currently -0.55. No institutional recommendations for buying, holding, or selling the stock have been reported.
The biotechnology sector, where Curis Inc. operates, saw an overall gain of 1.51%. In this sector, companies like Bionomics Ltd, Zyversa Therapeutics, and Nutriband Inc. showed significant stock price increases. Additionally, Zyversa Therapeutics and Bionomics Ltd were highly active, with turnover rates of 5541.17% and 2434.29%, respectively.
Curis Inc. is a biotechnology firm focused on developing and commercializing innovative therapeutics in the field of immuno-oncology and precision oncology. Its pipeline includes treatments for solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, and hematological cancers, featuring products like CUDC-907, CA-170, CA-4948, CA-327, and Erivedge.
